Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 20 July 2018

Indication(s)

ADROVANCE is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency. It reduces the risk of vertebral and hip fractures.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000759
Orphan designation No
Date First Approved 04-01-2007
Type Medicinal product subject to medical prescription
Marketing authorisation holder Merck Sharp & Dohme B.V.